[Treatment of immunodeficient conditions caused by viral infection with the Soviet immunomodulator kemantan in patients with pulmonary tuberculosis]. / Lechenie immunodefitsitnykh sostoianii, vyzvannykh perenesennoi virusnoi infektsiei, otechestvennym immunomoduliatorom kemantanom u bol'nykh tuberkulezom legkikh.

Observation of 219 patients with pulmonary tuberculosis was made to study the effect of acute respiratory viral infection (ARVI) on the course of the disease. The affected were divided into 2 groups: 136 subjects who had ARVI and 83 persons who did not have it during their stay at a hospital. Patients with infiltrative pulmonary tuberculosis, and young and middle-aged men were prevalent in both groups. It was found that ARVI promoted the aggravation of a specific process in the lungs in 19.1 per cent of the patients. Keeping in mind a large proportion of aggravations and low immunologic indices as a consequence of ARVI, 14 patients were put on kemantan. Study of the immune status of the patients who had ARVI and received kemantan demonstrated a significant increase in the formation of blasts and the concentration of T cells whose functional activity tended to rise. At the same time the above-mentioned indices remained intact or tended to drop in patients receiving no kemantan. The Soviet immunomodulator kemantan is recommended for a combined treatment of the pulmonary tuberculosis patients who had intercurrent viral infection to stimulate cellular immune defences and prevent an aggravation of the specific process.

[Effect of acute respiratory viral infection on the indicators of immunity in patients with pulmonary tuberculosis]. / Vliianie ostroi respiratornoi virusnoi infektsii na pokazateli immuniteta u bol'nykh tuberkulezom legkikh.

To study the impact of acute respiratory viral infection (ARVI) on the course of pulmonary tuberculosis, 150 cases with this condition were under observation. These patients were divided into 2 groups: 88 subjects who had ARVI and 62 persons who did not have it, being in hospital. In the both groups those suffering from infiltrative and focal pulmonary tuberculosis were predominant. ARVI is conducive to the aggravation of a specific process in the lungs, which was registered in 27.3% of the cases who had had ARVI, and impede the reactions of cellular immunity to restore, which can be observed during chemotherapy. Among those who had ARVI, 68.4% of the patients demonstrated a decrease in T-cells and blast transformation with PHA. A significant drop in the number of T-lymphocytes and their functional activity, as a consequence of ARVI, promotes the deterioration of the above specific process. ARVI affects the efficacy of the in-patient treatment and decreases the proportion of patients with cavity closure.